U.S. FDA panel backs Puma Biotech's breast cancer drug
WASHINGTON (Reuters) - Puma Biotechnology Inc's experimental breast cancer drug reduces the risk of disease recurrence and should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health